S&D Pharma is a UK-based company that represents global pharmaceutical companies and manages the promotion and distribution of their products in Central Europe.

Under the agreement, Cipla will sell its respiratory products in the Czech Republic and Slovakia through a Cipla-owned sales force team, managed by Cipla. S&D Pharma will physically distribute all products, including respiratory products, with the number of products included in this portfolio expected to increase over the next few years.

The first product expected to be launched in the countries is expected to be the fixed-dose combination fluticasone/salmeterol, which will be marketed under the name Fullhale. The drug is a generic of GlaxoSmithKline’s asthma treatment Advair (fluticasone/salmeterol).

Cipla has already launched the product in Croatia, under the name Duohal, as well as in Germany and Sweden. In Germany the product is distributed under the name Serroflo and in Sweden as Salmeterol/Fluticasone Cipla.

Sandoz, the generics unit of Swiss pharma giant Novartis, has also gained approval for its generic version of fluticasone/salmeterol, AirFluSal Forspiro, in Belgium, Bulgaria, Denmark, Germany, Hungary, Norway, Romania, and Sweden [1].

Related Articles
Sandoz gains Danish approval for innovative asthma inhaler

Advair could face competition from generics as early as 2016

Reference
1.   GaBI Online - Generics and Biosimilars Initiative. Sandoz gains Belgian approval for generic inhalation device [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2014 Sep 19]. Available from: www.gabionline.net/Generics/News/Sandoz-gains-Belgian-approval-for-generic-inhalation-device

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2014 Pro PharmaCommunications International. All Rights Reserved.